Rhythio Medical

Executive Summary

Rhythio Medical is a privately held medical device company based in Minneapolis, founded in 2019, focused on developing innovative implantable devices for cardiac rhythm management and heart failure treatment. The company aims to address significant unmet needs in electrophysiology by leveraging novel technologies to improve patient outcomes and reduce complications associated with existing therapies. Rhythio's lead product candidates target key areas in cardiac pacing and resynchronization, with a design emphasis on miniaturization, longevity, and advanced sensing capabilities. While still in early development stages, the company has demonstrated preclinical feasibility and is progressing toward first-in-human studies. Rhythio operates in a competitive landscape dominated by large incumbents, but its differentiated approach could capture market share in underserved segments. The management team brings deep experience from established medtech firms, positioning the company for potential strategic partnerships or acquisition interest as clinical data matures.

Upcoming Catalysts (preview)

• H1 2027First-in-human study initiation60% success
• Q4 2026FDA breakthrough device designation50% success
• Q2 2027Series B funding round completion70% success